MedPath

Validation of a Multi-gene Test for Lung Cancer Risk

Active, not recruiting
Conditions
Lung Cancer
Interventions
Genetic: Lung Cancer Risk Test
Registration Number
NCT01130285
Lead Sponsor
University of Toledo Health Science Campus
Brief Summary

The purpose of this study is to determine the validity of a multi-gene Lung Cancer Risk Test (LCRT). In the process, the investigators will establish a bank of NBEC samples and corresponding blood samples from individuals demographically at increased risk for lung cancer.

Detailed Description

Because more than 160,000 individuals die of lung cancer/year in the United States alone, it is important to use the best possible methods to determine whether increased surveillance of individuals at highest risk for lung cancer will result in reduced lung cancer mortality. The Lung Cancer Risk Test (LCRT) proposed for evaluation promises to accurately identify the 10-15% of the population that is most susceptible to lung cancer based on genetic predisposition. More than 90 million individuals in the United States alone are demographically at high risk for lung cancer and potential candidates for increased surveillance.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
403
Inclusion Criteria
  • 20 or more pack year smoking history
  • clinical need for diagnostic bronchoscopy or consent to study driven bronchoscopy
Exclusion Criteria
  • Lung Cancer within 3 months after the date of enrollment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Non-Lung Cancer, Heavy SmokerLung Cancer Risk TestSubjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
Primary Outcome Measures
NameTimeMethod
Accuracy of LCRT to predict incidental lung cancerfrom time of enrollment

Time of diagnosis of incidental lung cancer will be compared to value of the investigational device, the Lung Cancer Risk Test (LCRT).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

The Toledo Hospital

🇺🇸

Toledo, Ohio, United States

Mercy St. Vincent Medical Center

🇺🇸

Toledo, Ohio, United States

University of Toledo, Health Science Campus

🇺🇸

Toledo, Ohio, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Inova Fairfax Hospital

🇺🇸

Falls Church, Virginia, United States

Tennessee Valley Veterans Admin.

🇺🇸

Nashville, Tennessee, United States

Vanderbilt

🇺🇸

Nashville, Tennessee, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Ohio State University

🇺🇸

Columbus, Ohio, United States

National Jewish Health

🇺🇸

Denver, Colorado, United States

Henry Ford

🇺🇸

Detroit, Michigan, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath